StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research report issued on Thursday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

NASDAQ:ADXS opened at $0.03 on Thursday. The company has a market cap of $1.22 million, a P/E ratio of 0.00 and a beta of 1.63. The stock’s fifty day moving average price is $0.03 and its two-hundred day moving average price is $0.04. Ayala Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $1.49.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.